Managing immune-related adverse events to ipilimumab: A nurse's guide

Clinical Journal of Oncology Nursing

Volumn 16, Issue 2, 2012, Pages

  Rubin, Krista M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MONOCLONAL ANTIBODY;

HUMAN; IMMUNOLOGY; NEOPLASM; NURSING; REVIEW; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; HUMANS; NEOPLASMS; T-LYMPHOCYTES;

EID: 84859177214     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/12.CJON.E69-E75     Document Type: Review

References (31)

1. Amin, A., De Pril, V., Hamid, O., Wolchock, J., Maio, M., Neyns, B.,... O'Day, S. (2009). Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity [Abstract 9037]. Retrieved from http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34254
2. Atkins, M.B., Kunkel, L., Sznol, M., & Rosenberg, S.A. (2000). High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer Journal From Scientific American, 6(Suppl. 1), S11-S14.
3. Attia, P., Phan, G.Q., Maker, A.V., Robinson, M.R., Quezado, M.M., Yang, J.C.,... Rosenberg, S.A. (2005). Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. Journal of Clinical Oncology, 23, 6043-6053. doi:10.1200/JCO.2005.06.205
4. Beck, K.E., Blansfield, J.A., Tran, K.Q., Feldman, A.L., Hughes, M.S., Royal, R.E.,... Yang, J.C. (2006). Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. Journal of Clinical Oncology, 24, 2283-2289. doi:10.1200/JCO.2005.04.5716
5. Blansfield, J.A., Beck, K.E., Tran, K., Yang, J.C., Hughes, M.S., Kammula, U.S.,... Sherry, R.M. (2005). Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. Journal of Immunotherapy, 28, 593-598. doi:10.1097/01.cji.0000178913.41256.06
6. Bristol-Myers Squibb. (2011). Yervoy® (ipilimumab) [Prescribing information]. Retrieved from http://packageinserts.bms.com/pi/pi_yervoy.pdf
7. Chin, K., Ibrahim, R., Berman, D., Yellin, M., Lowy, I., Lin, R., & Hoos, A. (2008). Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an anti-CTLA4 therapy [Abstract 787P]. Annals of Oncology, 19(Suppl. 8), 8244-8245.
8. Downey, S.G., Klapper, J.A., Smith, F.O., Yang, J.C., Sherry, R.M., Royal, R.E.,... Rosenberg, S.A. (2007). Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen blockade. Clinical Cancer Research, 13, 6681-6688. doi:10.1158/1078-0432.CCR-07-0187
9. Drake, C.G., Jaffee, E., & Pardoll, D.M. (2006). Mechanisms of immune evasion by tumors. Advances in Immunology, 90, 51-81. doi:10.1016/S0065-2776(06)90002-9
10. Dummer, R., Maio, M., Hamid, O., O'Day, S.J., Richards, J.,... Weber, J.S. (2010, September). Time to onset and resolution of immune-related adverse events associated with ipilimumab therapy in patients with advanced melanoma [Abstract P-0004]. Poster presented at the 14th Perspectives in Melanoma in Amsterdam, the Netherlands.
11. Hodi, F.S., Butler, M., Oble, D.A., Seiden, M.V., Haluska, F.G., Kruse, A.,... Dranoff, G. (2008). Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences, 105, 3005-3010. doi:10.1073/pnas.0712237105
12. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B.,... Urba, W.J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363, 711-723. doi:10.1056/NEJMoa1003466
13. Hoos, A., Ibrahim, R., Korman, A., Abdallah, K., Berman, D., Shahabi, V.,... Humphrey, R. (2010). Development of ipilimumab: Contribution to a new paradigm for cancer immunotherapy. Seminars in Oncology, 37, 533-546.
14. Kruit, W.H., van Ojik, H.H., Brichard, V.G., Escudier, B., Dorval, T., Dréno, B.,... Marchand, M. (2005). Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. International Journal of Cancer, 117, 596-604. doi:10.1002/ijc.21264
15. Ledezma, B., Binder, S., & Hamid, O. (2011). Atypical clinical response patterns to ipilimumab. Clinical Journal of Oncology Nursing, 15, 393-403. doi:10.1188/11.CJON.393-403
16. Legha, S.S., Ring, S., Bedikian, A., Plager, C., Eton, O., Buzaid, A.C., & Papadopoulos, N. (1996). Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Annals of Oncology, 7, 827-835.
17. Little, R.F., Pluda, J.M., Wyvill, K.M., Rodriguez-Chavez, I.R., Tosato, G., Catanzaro, A.T.,... Yarchoan, R. (2006). Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood, 107, 4650-4657. doi:10.1182/blood-2005-11-4455
18. Lutzky, J., Wolchok, J., Hamid, O., Lebbe, C., Pehamberger, H., Linette, G.,... O'Day, S. (2009). Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials [Abstract 9034]. Retrieved from http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34815
19. Minor, D., Chin, K., & Kashani-Sabet, M. (2009). Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biotherapy and Radiopharmaceuticals, 24, 321-325.
20. National Comprehensive Cancer Network. (2011). NCCN Clinical Practice Guidelines in Oncology: Melanoma [v.4.2011]. Retrieved from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
21. Phan, G.Q., Yang, J.C., Sherry, R.M., Hwu, P., Topalian, S.L., Schwartzentruber, D.J.,... Rosenberg, S.A. (2003). Cancer regression and autoimmunity induced by cytotoxic T lympho cyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences, 100, 8372-8377. doi:10.1073/pnas.1533209100
22. Ribas, A., Chmielowski, B., & Glaspy, J.A. (2009). Do we need a different set of response assessment criteria for tumor immunotherapy? Clinical Cancer Research, 15, 7116-7118. doi:10.1158/1078-0432.CCR-09-2376
23. Ridolfi, L., & Ridolfi, R. (2009). Anti-CTLA-4 therapy in melanoma: Role of ipilimumab (MDX-010). Expert Review of Dermatology, 4, 199-210. doi:10.1586/edm.09.11
24. Robert, C., & Ghiringhelli, F. (2009). What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist, 14, 848-861.
25. Saenger, Y.M., & Wolchok, J.D. (2008). The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: Patient cases. Cancer Immunity, 8, 1.
26. Tarhini, A., Lo, E., & Minor, D.R. (2010). Releasing the brake on the immune system: Ipilimumab in melanoma and other tumors. Cancer Biotherapy and Radiopharmaceuticals, 25, 601-613.
27. van Baren, N., Bonnet, M.C., Dréno, B., Khammari, A., Dorval, T., Piperno-Neumann, S.,... Boon, T. (2005). Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. Journal of Clinical Oncology, 23, 9008-9021. doi:10.1200/JCO.2005.08.375
28. Weber, J. (2009). Ipilimumab: Controversies in its development, utility, and autoimmune adverse events. Cancer Immunolology, Immunotherapy, 58, 823-830. doi:10.1007/s00262-008-0653-8
29. Weber, J., Thompson, J.A., Hamid, O., Minor, D., Amin, A., Ron, I.,... O'Day, J. (2009). A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clinical Cancer Research, 15, 5591-5598. doi:10.1158/1078-0432.CCR-09-1024
30. Wolchok, J.D., Hoos, A., O'Day, S., Weber, J.S., Hamid, O., Lebbé, C.,... Hodi, F.S. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clinical Cancer Research, 15, 7412-7420. doi:10.1158/1078-0432.CCR-09-1624
31. Yang, J.C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian S.L.,... Rosenberg, S.A. (2007). Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. Journal of Immunotherapy, 30, 825-830. doi:10.1097/CJI.0b013e318156e47e